On August 28, 2018 AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) reported that Michael Bailey, president and chief executive officer, will participate in the following investor conferences (Press release, AVEO, AUG 28, 2018, View Source [SID1234529103]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 3:25 p.m. Eastern Time. The conference is being held at the New York Marriott East Side Hotel.

20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC., on Wednesday, September 5, 2018 at 10:25 a.m. Eastern Time. The conference is being held at the St. Regis New York Hotel.

A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw conference can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

On August 28, 2018 Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, reported that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the terms of two option agreements between Genprex and MD Anderson pertaining the use of TUSC2, the active agent in Genprex’s lead product candidate Oncoprex, in combination with immunotherapies and the development and the use of biomarkers to predict patient response to TUSC2 therapy (Press release, Genprex, AUG 28, 2018, View Source [SID1234529104]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These agreements will provide the opportunity to obtain additional patent protection for our TUSC2 gene therapy platform," said Rodney Varner, CEO of Genprex. "With these amended agreements in place, we will continue to advance and expand our clinical development program with Oncoprex for the treatment of non-small cell lung cancer and other potential therapeutic targets."

The first amended agreement provides Genprex with an option to exclusively license patent applications and related intellectual property relating to methods of treating cancer by combining TUSC2 with any of the immune checkpoint inhibitors known to stimulate immune responses, including but not limited to nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), and anti-KIR antibodies such as lirilumab.

Researchers at MD Anderson reported data from preclinical research at the 2017 meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) demonstrating that TUSC2 alone or in combination with checkpoint blockade (anti-PD-1 and/or anti-CTLA4) significantly prolonged mouse survival in a non-small cell lung cancer (NSCLC) metastasis model compared to checkpoint blockade alone. The greatest increase in survival was seen with TUSC2 combined with checkpoint blockade. The treatment response was associated with high infiltration of NK cells and CD8 T cells, and low infiltration of myeloid-derived suppressor cells (MDSC) in the tumor microenvironment.

The second amended agreement provides Genprex with an option to exclusively license an issued U.S. patent, foreign patent applications, and related intellectual property pertaining to methods for predicting a patient’s response to a TUSC2 therapy and methods for treating a patient previously predicted to have a favorable response to a TUSC2 therapeutic in conjunction with an epidermal growth factor receptor (EGFR) inhibitor and/or a protein kinase inhibitor.

Each amendment extends the term of the related option agreement to March 13, 2019, in consideration of the payment of $25,000.

On August 28, 2018 Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) reported it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, Aurinia Pharmaceuticals, AUG 28, 2018, https://ir.auriniapharma.com/news/detail/122/aurinia-announces-participation-at-the-20th-annual-global-investment-conference-in-new-york-city-september-4-6-2018 [SID1234529090]). The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company’s business on Thursday, September 6 at 10:50am ET.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.

On August 28, 2018 VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that Jeff Baxter, President and CEO, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Thursday, September 6, 2018, at 12:05 PM ET (Press release, VBI Vaccines, AUG 28, 2018, View Source [SID1234529430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and a subsequent replay may be accessed by visiting the Investors page of VBI’s website at: www.vbivaccines.com/investors/events-presentations/. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

Event: 20th Annual Rodman & Renshaw Global Investment Conference sponsored by H.C. Wainwright & Co., LLC
Date: Thursday, September 6, 2018
Time: 12:05 – 12:30 p.m. ET
Location: Louis XVI A, St. Regis New York Hotel in New York City
Webcast: View Source

On August 28, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem cell transplant, or HSCT, in order to support the patient’s newly transplanted immune system before it becomes fully functional, reported that it is scheduled to attend the following investor conferences in September 2018 (Press release, Kiadis, AUG 28, 2018, View Source [SID1234529092]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 8th Annual Biotech Symposium

September 7, 2018, Goldman Sachs Offices, River Court, 120 Fleet Street, London, UK

Oppenheimer Fall Summit focused on Specialty Pharma and Rare Disease

September 26-27, 2018, The Langham, 400 5th Avenue, New York, USA

KBC Securities 6th Biotech and Healthcare Conference

September 27, 2018, Convene Grand Central, 101 Park Avenue, New York, USA

For more information, please contact:

Kiadis Pharma:

Karl Hård, Head of IR & Communications

Tel. +31 611 096 298

[email protected]

Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile

Tel: +44 203 714 1787

[email protected]